FDA Approves Blincyto^® (Blinatumomab) in CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor Acute Lymphoblastic Leukemia (B-ALL) in the Consolidation Phase

Amgen announced the US FDA has approved BLINCYTO® for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of measurable residual disease status.